** Shares of cell-based therapy company THMO.O rise 5.4%
to $6.16
** Co files patent applications for a point-of-care device
which improves the speed and accuracy of certain tests to detect
COVID-19 antibodies from a single drop of blood urn:newsml:reuters.com:*:nPn7zWDZVa
** THMO is also developing convalescent plasma and antibody
therapeutic approaches against COVID-19 in collaboration with
joint venture partner ImmuneCyte Life Sciences Inc urn:newsml:reuters.com:*:nPn4TGr9Pa
** Including session's gain, shares up ~40% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))